Diaverum’s 2022 report shows how the company is accelerating its ESG agenda
Diaverum, the Swedish-born, multinational healthcare organisation has today released its 2022 Environmental, Social and Governance (ESG) Report. Alongside information related to the company’s non-financial performance last year, the report shows how Diaverum’s focus on driving forward its ESG agenda has grown in importance and scale, particularly in light of the events that have played a dominant role on the world stage over the past three years - the global pandemic, the war in Ukraine and the resulting economic recession.
The societal and economic challenges that these combined events have created and that are still experienced today, pose health and well-being risks to our patients, staff and communities alike, as well as a strain on national healthcare systems’ capacity to serve society. This has highlighted a long-coming and unfortunate trend - CKD continues to be a global, escalating challenge that affects about 10% of the world’s adult population, and it’s estimated that the number of people requiring dialysis will continue to grow at approximately 6% every year by 2025. This is making CKD one of the leading causes of death worldwide today, the impact of which is felt primarily in low and middle-income countries.
Dimitris Moulavasilis, Diaverum CEO, said: “As a response to this, we are accelerating our ESG journey at Diaverum and in order to explain how we are doing it, we are proud to release our 2022 ESG report, our most comprehensive non-financial performance reporting to date. It includes clearer ambitions, solid governance controls information and a well-defined ESG roadmap for the years to come, covering our strategy and actions that ensure our stakeholder-centric business approach. But it is not only about that – this report is a tool we are equipping society with as means of holding us at Diaverum accountable for our commitments and impact on society & the environment”.
As a healthcare organisation that provides life-enhancing renal care to patients with Chronic Kidney Disease (CKD) across 23 countries in 4 continents, Diaverum places great importance on the impact it has on the environment & the communities it operates in, reporting the company’s ESG performance annually and continuously working to increase the transparency and accountability of its ESG disclosure. Since 2021, Diaverum has been aligning its ESG report with the Sustainability Accounting Standards Board (SASB) - Health Care Delivery Industry Standard.
As Diaverum welcomed almost 700 new patients every month last year, its non-financial performance in 2022 was robust and included:
- a continued strong track record of improving key medical outcomes for patients – e.g. 24.1% improvement in the company’s Clinical Performance Measurement since 2003, and 11.7% reduction in hospitalisation days per patient per year since 2011
- significant strides made in the company’s digital transformation;
- the development of a workplace and clinical environment that resulted in record Net Promoter Scores (NPS), captured both in patient (66.1%) and employee (81%) surveys;
- decisive action in promoting health literacy & empowerment among the communities the company operates in;
- the implementation of mechanisms to collect and act on the experiences from patients.
Stephanie De Sury, Global ESG Manager, said: “As with previous years, the report is organised across five fundamental pillars, which are based on our biennial materiality assessment priorities: patients; employees and well-being; access to care; operating responsibly; and the environment. It not only highlights our non-financial performance but also outlines our approach in meeting the expectations of our internal and external stakeholders, while respecting the environment and understanding our impact as an ethical business.”
Diaverum’s ESG roadmap
To ensure that we continue to make progress and accelerate the delivery of our ESG agenda, we have developed a comprehensive roadmap to mid-2024 that outlines specific goals and actions, explained in detailed in our 2022 report. This roadmap focuses on:
- aligning and further integrating the Sustainable Development Goals (United Nations 2030 Agenda) and Ethical Principles in Health Care (EPiHC) into our business development plans
- reshaping our ESG reporting in order to be compliant with the Corporate Sustainability Reporting Directive (CSRD) according to the new European Sustainability Reporting Standards (ESRS), and preparing to subject it to external and independent third-party verification in the next 2 years
- defining specific goals in each of our ESG framework pillars and improving the measurement of our impact on our key material topics
- clarifying our environmental strategy for the medium and long term
- cementing ESG principles within our ongoing value propositions
Diaverum’s 2022 ESG report is available through the company’s website.
Marianna Sofocleous
Global Communications & Editorial Manager
marianna.sofocleous@diaverum.com
About Diaverum
Diaverum is a Swedish-born, multinational healthcare organisation that provides life-enhancing renal care to patients with Chronic Kidney Disease (CKD), empowering them to live fulfilling lives.
Our vision is to transform the industry through patient-centric digital innovations, delivering and broadening access to the highest quality of care.
Our focus is to provide renal care tailored to patients’ needs and choices, offering a portfolio of treatments ranging from preventive care, haemodialysis, peritoneal dialysis and home care, to coordination of patients’ comorbidities and holiday dialysis.
As a global leader and the largest independent renal service provider in Europe, we care for around 39,000 patients across 440 clinics in 23 countries globally. Diaverum employs around 13,000 people worldwide and is headquartered in Malmö, Sweden.
Tags:
